Tucatinib Plus Trastuzumab Approved for HER2+ CRC

The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.
FDA Approvals

source https://www.medscape.com/viewarticle/987242?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?